← all works
Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial
Why is this work in the frame?
A frame that forgets how it found something cannot be audited. These are the routes that admitted this work.
Canadian funderA Canadian agency funded it. The work may carry no Canadian affiliation at all.
No Canadian affiliation. An affiliation-only frame — the usual design — would never have seen this work. It is one of the works that make the case for inverting the frame.
Abstract
No abstract. This is not a gap in this database — OpenAlex has none either. 23.3% of the frame is in this state, and the screen finds HALF as much metaresearch here, so the absence is a measured bias rather than a missing field.
The record
- Venue
- The Lancet Oncology
- Topic
- Prostate Cancer Treatment and Research
- Field
- Medicine
- Canadian institutions
- —
- Funders
- Institute of Cancer ResearchNational Cancer InstituteInstitut National Du CancerSanofiRocheBayerAstraZenecaUnicancerNovartisPfizerAmgen
- Keywords
- MedicineDocetaxelAndrogen deprivation therapyProstate cancerInternal medicineOncologyEstramustineClinical endpointChemotherapyGoserelinProstate-specific antigenUrologyCancerRandomized controlled trial
- Has abstract in OpenAlex
- no